| Document |
Document Title |
|
WO/2023/027553A1 |
The present invention relates to a composition for preventing, treating or ameliorating poor ovarian response syndrome, comprising an RGMc-derived protein. When the composition according to an aspect is used, this may induce the normal d...
|
|
WO/2023/020178A1 |
A use of a cell-free fat extract for preparing a composition or preparation. The composition or preparation is used for preventing and/or treating vaginal atrophy. The cell-free fat extract has an excellent therapeutic effect on vaginal ...
|
|
WO/2023/015180A1 |
Described are improved processes for the preparation of iodized fatty acid esters from free fatty acids via in-situ formation of hydroiodic acid using silane chemistry.
|
|
WO/2023/007088A1 |
The oral food supplement which makes it possible to protect against infertility caused by premature ovarian insufficiency or by endometriosis or by polycystic ovary syndrome (PCOS) in women, or by low sperm count in men, this being both ...
|
|
WO/2023/005973A1 |
A use of one or more lipid compounds in the delivery of nucleic acids, and a lipid nucleic acid mixture, pharmaceutical composition or kit comprising the lipid compounds and nucleic acids. The lipid compounds can promote the absorption, ...
|
|
WO/2022/165097A9 |
The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for tr...
|
|
WO/2023/009445A1 |
A pharmaceutical composition for use in the treatment of bacterial vaginosis, wherein said composition comprises a poloxamer, a stabilization polymer, and an active ingredient for treating the bacterial vaginosis, preferably clindamycin,...
|
|
WO/2023/007312A1 |
The present invention relates to a method for providing progestogen only contraception. The method consists of orally administering to a human subject desiring contraception a tablet consisting of about 0.115 mg to about 0.145 mg of levo...
|
|
WO/2023/005130A1 |
The present invention relates to the technical field of traditional Chinese medicine research for infertility, and in particular to a traditional Chinese medicine composition for treating the infertility, and a preparation method therefo...
|
|
WO/2023/003130A1 |
Provided is a pharmaceutical composition for the prevention or treatment of Asherman's syndrome or complications thereof, comprising mitochondria as an active ingredient. The pharmaceutical composition alleviates or treats endometrial ad...
|
|
WO/2023/001246A1 |
A method for preparing a polypeptide-containing fetal sheep zymolyte, mainly comprising the following steps: (1) taking a fetal sheep homogenate or dry powder, and adding water to and stirring same; (2) heating same to 50-60°C, adjustin...
|
|
WO/2023/000418A1 |
An altrenogest injection, a preparation method therefor, and an application thereof. Each 100 mL of the altrenogest injection comprises the following components: 0.1-35 g of altrenogest, 0.01-70 mL of polyethylene glycol, the remainder b...
|
|
WO/2023/286012A1 |
The present invention relates to a hydrolyzed collagen powder having specific characteristics, a. process for its preparation and uses thereof, in therapy and so on.
|
|
WO/2023/284466A1 |
Disclosed is the use of a cell-free fat extract for preparing a composition or a preparation. The composition or the preparation is used for preventing and/or treating ovarian insufficiency and/or complications thereof. The cell-free fat...
|
|
WO/2023/283578A1 |
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administer...
|
|
WO/2023/280937A1 |
The present invention relates to the use of lactic acid and/or lactic acid salts for treating and/or preventing vaginal symptoms, caused by a lack of oestrogen, of genitourinary syndrome of menopause, postmenopausal atrophic vaginitis, s...
|
|
WO/2023/282145A1 |
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing ...
|
|
WO/2023/280765A1 |
The present invention relates to the choline salt (cholinate) of 2-(1-cyclobutyl-1H- pyrazol-4-yl)-5-[([1-[2-fluoro-4-(trifluoromethyl)- phenyl]cyclopropyl}carbonyl)amino]benzoic acid. In particular, the invention relates to the compound...
|
|
WO/2023/280309A1 |
The present disclosure relates to salt types of a tricyclic tetrahydro isoquinoline derivative. Specifically, the present disclosure relates to different salt types of a compound as represented by formula (I) and a preparation method the...
|
|
WO/2023/280243A1 |
Provided are miR-339 capable of activating a breast cancer-related gene, an miR-339-enhancer-target gene network activation model, and applications thereof. The locus of the miR-339 coincides with the histone modification marker H3K4me1o...
|
|
WO/2023/281430A1 |
The present invention relates to a complex between at least one lactoferrin and/or a hydrolyzate thereof with at least one pullulan, and a composition comprising said complex and at least one physiologically acceptable excipient, for ora...
|
|
WO/2023/272407A1 |
The present invention relates to the use of a combination of estretol (E4) and progesterone (P4) to prepare a medicine that is useful in the treatment of endometriosis. The medicine of the invention does not lower progesterone-receptor (...
|
|
WO/2023/272376A1 |
Migration of human peripheral leukocytes in response to chemotactic factors during pregnancy. The methods include determining the likelihood of a pregnant subject undergoing delivery within about 7 days by obtaining peripheral leukocytes...
|
|
WO/2023/276861A1 |
The present invention improves the sperm finding of mammalian animals, and in particular, male infertility patients. This composition for oral ingestion, which contains ergothioneine as an active component, is administered orally to a ...
|
|
WO/2022/247920A9 |
The present invention relates to a quinolinamine compound, a preparation method therefor and an application thereof in pharmaceuticals. Specifically, the present invention relates to a quinolinamine compound as represented by general for...
|
|
WO/2023/275088A1 |
A selective estrogen receptor modulator and/or an aromatase inhibitor (A) for use in a method of preventing or treating gynecomastia and/or mastalgia, wherein said method comprises administering said selective estrogen receptor modulator...
|
|
WO/2023/275132A1 |
The present invention relates to the field of medicine, in particular to internal and aesthetic regenerative medicine. More specifically, the present invention relates to a composition suitable for use as a transport medium for adipose t...
|
|
WO/2023/272694A1 |
The present invention relates to the field of vitamin C sustained release technology, and specifically relates to a vitamin C and zinc sustained release tablet and a preparation method therefor. Said tablet is made of a tablet-shaped dru...
|
|
WO/2022/269489A1 |
The object of the invention relates to an association of molecular oxygen and hyaluronic acid or its salts for use in the treatment of symptomatology associated with vulvar vestibulitis.
|
|
WO/2022/270112A1 |
[Abstract] Corosolic acid improves insulin resistance and recovers an insulin function that is deteriorated with age. As a result, the insulin sensitivity in an aged person is improved and the metabolism in all cells gets active. [Proble...
|
|
WO/2022/262870A1 |
Provided are a molecular marker combination of ovarian activation, and the use thereof in the preparation of a kit or gene chip for studying ovarian activation or detecting diseases related to abnormal ovarian activation. Also provided i...
|
|
WO/2022/264127A1 |
Described herein are compositions which can be used to alleviate vaginal dryness and vaginal atrophy. The compositions comprise a cannabinoid and a phytoestrogen. Optionally, the composition further comprises a prebiotic agent, preferabl...
|
|
WO/2022/264114A2 |
The invention described herein provides a reactive oxygen species (ROS) responsive linker based on diazaborines (DAB) scaffold. Here we show the ability of diazaborines (DABs) scaffolds to be stable in different biocompatible conditions ...
|
|
WO/2022/265537A1 |
The invention relates to medicine, and more particularly to urology, and can be used for treating erectile dysfunction (ED). The technical result of the invention for which a patent is sought consists in stimulating microcirculation in e...
|
|
WO/2022/257863A1 |
Disclosed are a use of oxytocin or a derivative thereof in the preparation of a preparation for treating or improving lactation insufficiency, and a composition thereof. An improvement method for treating postpartum breast ptosis may be ...
|
|
WO/2022/259195A1 |
The present invention relates to an oral composition comprising at least a citrus fruit extract, preferably a lemon extract from Citrus limon (L.) Osbeck, and at least an Ashwagandha (Withania somnifera (L.) Dunal) extract, and use there...
|
|
WO/2022/260016A1 |
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically ...
|
|
WO/2022/255568A1 |
The present invention relates to a composition for preventing or treating vaginitus, having Lactobacillus rhamnosus and Lactobacillus acidophilus mixed at a certain ratio, and, by using the composition for preventing or treating vaginiti...
|
|
WO/2022/255284A1 |
The purpose of the present invention is to provide an oral administration agent for pregnant women for increasing the concentration of short-chain fatty acids in the blood of a pregnant woman or the fetus, for imparting resistance to obe...
|
|
WO/2022/252663A1 |
A use of a composition of alcohol and a cooling agent in regulating a sexual function, protecting a cardiovascular and cerebrovascular system, promoting hepatocyte regeneration, fighting against a tumor, and improving the immunity and sl...
|
|
WO/2022/256556A1 |
The invention provides methods of treating and inhibiting mastitis in dairy cows, in need thereof, wherein said method comprises: administering pegbovigrastim to the cow during the late lactation stage and about the dry-off day.
|
|
WO/2022/255978A1 |
The invention relates to a composition used for eliminating genital odors and preventing odor formation.
|
|
WO/2022/251699A1 |
Provided herein are compositions and methods for the treatment of sexual dysfunction and related diseases, disorders, and conditions. An aspect of the present disclosure is a combination comprising at least two compounds independently se...
|
|
WO/2022/251393A1 |
Disclosed herein are intravaginal ring (IVR) devices comprising barriers that may be metal, polymeric or combinations of metal and polymeric. The IVRs are useful for contraception, treating and/or preventing sexually transmitted diseases...
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/249170A1 |
The invention provides methods for induction of pregnancy in a couple in need thereof wherein the male subject in said couple has been diagnosed as sub-fertile, said method comprising administering systemically to said male subject a pha...
|
|
WO/2022/248269A1 |
A composition for topical application to the oral cavity, for the use in pregnant women to reduce the risk of preterm birth, comprising an ester of vitamin E with a carboxylic acid of formula R-COOH, in which R is an alkyl radical having...
|
|
WO/2022/244815A1 |
Provided are lipid particles in which is encapsulated a nucleic acid, whereby: a vaccine for preventing and/or treating an infection by human papillomavirus type-6 and/or type-11 can be provided; and an E6 antibody and an E7 antibody to ...
|
|
WO/2022/241549A1 |
GHR-106 monoclonal antibody or antigen-binding fragments thereof are provided and used to modulate levels of reproductive hormones in vivo when administered to mammalian subjects. The GHR-106 monoclonal antibody or an antigen-binding fra...
|
|
WO/2022/240983A1 |
The present inventive concept relates to genetic variants, for example, ESR1 rs9340799, and the association of such genetic variants with increased weight gain among contraceptive users, such as contraceptive implant users. Embodiments o...
|
